Citigroup Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $76

Benzinga Newsdesk www.benzinga.com Positive 79.1%

Neg 0% Neu 0% Pos 79.1%

Citigroup analyst Eric Joseph maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $75 to $76.